Subsequently, a huge breakthrough also occurred after the adoption of PD-1 inhibitors in combination with chemotherapy in recurrent, locally advanced, or metastatic ESCC regardless of the PD-L1 expression. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.